Van Tuyl Christopher 4
4 · Immunovant, Inc. · Filed Jun 22, 2026
Research Summary
AI-generated summary of this filing
Immunovant (IMVT) CLO Christopher Van Tuyl Sells Shares
What Happened
Christopher Van Tuyl, Chief Legal Officer of Immunovant (IMVT), reported a sale of 2,634 shares on 2026-06-18 at $35.39 per share, generating roughly $93,217. The sale was a "sell-to-cover" to satisfy tax withholding when 6,872 restricted stock units (RSUs) vested on June 16, 2026. The filing indicates this sale was mandated by the issuer and was not a discretionary trade by the reporting person.
Key Details
- Transaction date and price: 2026-06-18, 2,634 shares sold at $35.39 each (≈ $93,217 total).
- Origin of shares: Related to RSUs granted Dec 16, 2024 (109,956 RSUs total); 6,872 RSUs vested on Jun 16, 2026 (per footnote).
- Net retained from this vesting: 6,872 vested − 2,634 sold = 4,238 shares likely retained after the sell-to-cover.
- Shares owned after transaction: Not specified in this Form 4.
- Filing/Timeliness: Form 4 filed Jun 22, 2026 (within the normal reporting window for a 6/18 transaction).
- Transaction type/code: Reported as a Sale (S); footnote clarifies the sale was to cover tax withholding (sell-to-cover) and not discretionary.
Context
This was a routine sell-to-cover tied to RSU vesting — common when companies require withholding taxes by selling a portion of vested shares. Such tax-motivated sales are not generally taken as a directional signal about the insider’s view of the stock; purchases or discretionary sales are typically more informative about sentiment.
Insider Transaction Report
- Sale
Common Stock
[F1]2026-06-18$35.39/sh−2,634$93,217→ 180,597 total
Footnotes (1)
- [F1]On December 16, 2024, the holder was granted 109,956 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on December 18, 2024, of which 6,872 of these RSUs vested on June 16, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.